Nimodipin Bayer (Nimodipine)

Nimodipine, the active ingredient in Nimodipin Bayer, is a calcium channel blocker presented as an oral tablet for oral use. It prevents cerebral vasospasm following subarachnoid hemorrhage in adult patients.

GNH USA supplies Nimodipin Bayer as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nimodipine is used in the cerebrovascular field to reduce complications after subarachnoid hemorrhage. - Subarachnoid hemorrhage: prevents cerebral vasospasm and associated delayed ischemic neurological deficits. - Aneurysmal SAH: reduces the incidence of delayed cerebral ischemia. - Post‑operative SAH care: supports vascular stability during the acute recovery phase.

Nimodipine may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Headache: mild to moderate intensity. - Dizziness or light‑headedness, especially on standing. - Nausea or gastrointestinal discomfort. - Flushing or warmth sensation. - Hypotension: transient blood pressure drop. - Peripheral edema: mild swelling of ankles or feet.

Serious or Rare Side Effects: - Severe hypotension or syncope. - Cardiac arrhythmias. - Hepatic dysfunction: elevated liver enzymes. - Allergic reactions: rash, pruritus, or angioedema. - Thrombocytopenia or other hematologic abnormalities.

Before prescribing Nimodipine, clinicians should consider several safety aspects. - Cardiovascular status: monitor blood pressure and heart rate, especially in patients with pre‑existing hypotension. - Hepatic function: assess liver enzymes; adjust use if significant impairment is present. - Concomitant vasodilators: avoid additive hypotensive effects. - Pregnancy and lactation: use only if potential benefit justifies potential risk, as safety data are limited. - Elderly patients: start at lower doses and monitor for dizziness or falls. - Store at ambient temperature: keep below 25 °C, retain in original packaging, and protect from moisture.

Nimodipine can interact with several drug classes, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase plasma concentrations and risk of toxicity. - Concurrent use with other potent vasodilators: can cause severe hypotension.

Moderate Interactions (Monitor Closely):\n- CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce therapeutic levels. - Beta‑blockers: may enhance bradycardia or hypotensive effects. - Diuretics: monitor electrolytes and blood pressure for additive effects.